¼¼°èÀÇ ¹üºÒ¾ÈÀå¾Ö ½ÃÀå : ÀÛ¿ë±âÀü, °¡°ÝÀü·«, À¯Åëä³Î, ÀÇ·á Á¦°øÀÚº° ¿¹Ãø(2025-2030³â)
Generalized Anxiety Disorder Market by Mode Of Action (Gamma-Aminobutyric Acid Receptors, Norepinephrine Modulators, Serotonin Modulators), Pricing Strategy, Distribution Channel, Healthcare Providers - Global Forecast 2025-2030
»óǰÄÚµå : 1576809
¸®¼­Ä¡»ç : 360iResearch Private Limited
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 191 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,939 £Ü 5,699,000
PDF, Excel & 1 Year Online Access (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 4,249 £Ü 6,147,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿Àϱâ¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 5,759 £Ü 8,332,000
PDF, Excel & 1 Year Online Access (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ Áö¿ª »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 6,969 £Ü 10,083,000
PDF, Excel & 1 Year Online Access (Enterprise User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹üºÒ¾ÈÀå¾Ö ½ÃÀåÀº 2023³â 21¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 22¾ï 3,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµÇ¸ç º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 5.42%·Î ¼ºÀåÇÏ¿© 2030³â 30¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹üºÒ¾ÈÀå¾Ö(GAD)´Â ÀÏ»ó »ýȰÀÇ ´Ù¾çÇÑ Ãø¸é¿¡ ´ëÇÑ °úµµÇϰí ÅëÁ¦ ÇÒ ¼ö¾ø´Â °ÆÁ¤À» Ư¡À¸·ÎÇÏ´Â ¸¸¼º Á¤½Å ÁúȯÀ¸·Î Àü ¼¼°è ¼ö¹é¸¸ ¸íÀÌ ¾Î°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀå ¹üÀ§¿¡´Â Áõ»óÀ» °ü¸®ÇÏ°í ¿ÏÈ­Çϱâ À§ÇØ °í¾ÈµÈ ÀǾàǰ, Çൿ Ä¡·á ¼­ºñ½º ¹× µðÁöÅÐ Á¤½Å °Ç°­ Ç÷§ÆûÀÌ Æ÷ÇԵ˴ϴÙ. È¿°úÀûÀÎ Ä¡·áÀÇ Çʿ伺Àº °æÁ¦ ºÒÈ®½Ç¼º°ú COVID-19ÀÇ À¯Çà°ú °°Àº ¼¼°è ½ºÆ®·¹½º ¿äÀο¡ ÀÇÇØ ÁõÆøµÈ Á¤½Å°Ç°­ ¹®Á¦¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡¿Í À¯º´·üÀÇ »ó½Â¿¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù. 󹿾àºÎÅÍ ÀÎÁöÇൿ¿ä¹ý, Áø´Ü, Ä¡·á Áö¿øÀ» Á¦°øÇÏ´Â µðÁöÅÐ ¿ëµµ±îÁö, ±× ¿ëµµ´Â ´Ù¾çÇÕ´Ï´Ù. ÃÖÁ¾ »ç¿ëÃþÀº ÁַΠû¼Ò³â°ú ¼ºÀÎÀÌ¸ç ¼Ò¾Æ Áõ·Ê¿¡¼­ GADÀÇ ÀÎÁö°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â ¸ÂÃãÇü ÀÇ·áÀÇ Áøº¸, ±Þ¼ºÀåÇÏ´Â ¿ø°Ý ÀÇ·á ºÐ¾ß, ¸¶ÀεåÇ÷ç³×½º ¹× À£´Ï½º ¾Û µîÀÇ ºñ¾à¸®Àû °³ÀÔ¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ °­ÇÑ ¼ö¿ä µîÀÌ ÀÖ½À´Ï´Ù. ÅëÇÕ Ä¡·á ÇÁ·ÎÅäÄÝÀÇ °³¹ß°ú °³ÀÎÈ­ Ä¡·á ¿ä¹ýÀ» À§ÇÑ AI Ȱ¿ë¿¡´Â ÀáÀçÀûÀÎ ±âȸ°¡ Á¸ÀçÇÕ´Ï´Ù. ±×·¯³ª ÀÌ ½ÃÀåÀº Á¤½Å°Ç°­À» µÑ·¯½Ñ Æí°ß, Àϰü¼º ¾ø´Â Ä¡·áÈ¿°ú, ƯÈ÷ Àú°³¹ßÁö¿ª¿¡¼­ÀÇ Á¢±Ù¼º ¹®Á¦ µîÀÇ ÇѰ迡 Á÷¸éÇϰí ÀÖ½À´Ï´Ù. Áß¿äÇÑ °úÁ¦´Â ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú ¾ö°ÝÇÑ °Ç°­ °¡À̵å¶óÀÎ Áؼö¸¦ º¸ÀåÇÏ´Â °ÍÀÔ´Ï´Ù. Çõ½ÅÀûÀÎ ¼ºÀå ºÐ¾ß·Î´Â µðÁöÅÐ Áø´Ü ÅøÀÇ °­È­, Ä¡·áÀÇ Áøº¸¸¦ À§ÇÑ AI ÁÖµµÀÇ ÅëÂûÀÇ È®´ë, º¸´Ù Ä¡¹ÐÇÑ Ä¡·á¸¦ À§ÇÑ À¯ÀüüÇÐÀÇ È°¿ë µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.½ÃÀåÀÇ º»ÁúÀº ¿ªµ¿ÀûÀ̸ç, »õ·Î¿î ±â¼úÀÇ Áøº¸¿Í ÀüÀÎÀû ÄÉ¾î ¸ðµ¨¿¡ ´ëÇÑ ²÷ÀÓ¾ø´Â ÁøÈ­¿Í ÀûÀÀÀÌ ÇÊ¿äÇÕ´Ï´Ù. ±â¾÷Àº ÀÇ·á Á¢±Ù ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ ÀÇ·á ±â¼ú ±â¾÷°úÀÇ Çù·Â °ü°è¸¦ ÃËÁøÇÏ°í ¿ø°Ý Ä¡·á Á¦°øÀ» È®´ëÇÏ´Â µ¥ ÁÖ·ÂÇØ¾ßÇÕ´Ï´Ù. ¶ÇÇÑ Ä·ÆäÀÎÀ» ÅëÇØ »ç¶÷µéÀÇ ÀÎÁöµµ¸¦ ³ôÀÌ°í ½ºÆ¼±×¸¶¸¦ ÁÙÀÌ´Â °Íµµ ½ÃÀå È®´ë¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Àü·«¿¡ ¿ì¼±¼øÀ§¸¦ ºÎ¿©ÇÔÀ¸·Î½á ±â¾÷Àº ±âÁ¸ÀÇ °úÁ¦¿¡ È¿°úÀûÀ¸·Î ´ëóÇϸ鼭 È®´ëÇÏ´Â ¼ö¿ä¸¦ Ȱ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 21¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 22¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 30¾ï 9,000¸¸ ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 5.42%

½ÃÀå ¿ªÇÐ: ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â ¹üºÒ¾ÈÀå¾Ö ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¹üºÒ¾ÈÀå¾Ö ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ðÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ëÀ̳ª ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Porter's Five Forces: ÀÏ¹Ý ºÒ¾È Àå¾Ö ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂûÀ» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÀÏ¹Ý ºÒ¾È Àå¾Ö ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¹üºÒ¾ÈÀå¾Ö ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ¹üºÒ¾ÈÀå¾Ö ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

ÀÏ¹Ý ºÒ¾ÈÀå¾Ö ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ¹üºÒ¾ÈÀå¾Ö ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÀÏ¹Ý ºÒ¾È Àå¾Ö ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÎ¹®È­Çϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·«ºÐ¼® ¹× Ãßõ Àü¹ÝÀû ºÒ¾ÈÀå¾Ö ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

¹üºÒ¾ÈÀå¾Ö ½ÃÀåÀÇ Àü·«ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° ½ÃÀå, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ, ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

Á¦6Àå ¹üºÒ¾ÈÀå¾Ö ½ÃÀå ÀÛ¿ë±âÀüº°

Á¦7Àå ¹üºÒ¾ÈÀå¾Ö ½ÃÀå °¡°Ý Àü·«º°

Á¦8Àå ¹üºÒ¾ÈÀå¾Ö ½ÃÀå : À¯Åëä³Îº°

Á¦9Àå ¹üºÒ¾ÈÀå¾Ö ½ÃÀå ÇコÄɾî Á¾»çÀÚº°

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ¹üºÒ¾ÈÀå¾Ö ½ÃÀå

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¹üºÒ¾ÈÀå¾Ö ½ÃÀå

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¹üºÒ¾ÈÀå¾Ö ½ÃÀå

Á¦13Àå °æÀï ±¸µµ

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Generalized Anxiety Disorder Market was valued at USD 2.13 billion in 2023, expected to reach USD 2.23 billion in 2024, and is projected to grow at a CAGR of 5.42%, to USD 3.09 billion by 2030.

Generalized Anxiety Disorder (GAD) is a chronic mental health condition characterized by excessive and uncontrollable worry about various aspects of daily life, affecting millions worldwide. Its market scope encompasses pharmaceuticals, behavioral therapy services, and digital mental health platforms designed to manage and alleviate symptoms. The necessity for effective treatments stems from the heightened awareness and rising prevalence of mental health issues, amplified by global stressors such as economic uncertainties and the COVID-19 pandemic. Applications are manifold, ranging from prescription medications to cognitive-behavioral therapy and digital applications that offer diagnostic and therapeutic support. End-use demographics primarily include adolescents and adults, with a growing recognition of GAD in pediatric cases. Key growth factors influencing this market include advancements in personalized medicine, the burgeoning telehealth sector, and strong consumer demand for non-pharmacological interventions such as mindfulness and wellness apps. The potential opportunities exist in developing integrated treatment protocols and harnessing AI for personalized treatment regimens. However, the market faces limitations such as stigma surrounding mental health, inconsistent treatment efficacy, and accessibility issues, particularly in underdeveloped regions. A significant challenge is ensuring regulatory approvals and compliance with stringent health guidelines. Innovative areas for growth include the enhancement of digital diagnostic tools, expansion of AI-driven insights for therapeutic advancements, and leveraging genomics for better-targeted treatments. The nature of the market is dynamic, necessitating constant evolution and adaptation to emerging technological advances and holistic care models. Companies should focus on fostering collaborations with health-tech firms and expanding teletherapy offerings to address care accessibility issues. Additionally, increasing public awareness and reducing stigma through campaigns can play a critical role in market expansion. By prioritizing these strategies, businesses can capitalize on the growing demand while addressing existing challenges effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 2.13 billion
Estimated Year [2024] USD 2.23 billion
Forecast Year [2030] USD 3.09 billion
CAGR (%) 5.42%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Generalized Anxiety Disorder Market

The Generalized Anxiety Disorder Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Porter's Five Forces: A Strategic Tool for Navigating the Generalized Anxiety Disorder Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Generalized Anxiety Disorder Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Generalized Anxiety Disorder Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Generalized Anxiety Disorder Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Generalized Anxiety Disorder Market

A detailed market share analysis in the Generalized Anxiety Disorder Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Generalized Anxiety Disorder Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Generalized Anxiety Disorder Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Generalized Anxiety Disorder Market

A strategic analysis of the Generalized Anxiety Disorder Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Generalized Anxiety Disorder Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkermes plc, Allergan plc, AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, H. Lundbeck A/S, Jazz Pharmaceuticals plc, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Otsuka Holdings Co., Ltd., Pfizer Inc., Roche Holding AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Vanda Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Generalized Anxiety Disorder Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Generalized Anxiety Disorder Market, by Mode Of Action

7. Generalized Anxiety Disorder Market, by Pricing Strategy

8. Generalized Anxiety Disorder Market, by Distribution Channel

9. Generalized Anxiety Disorder Market, by Healthcare Providers

10. Americas Generalized Anxiety Disorder Market

11. Asia-Pacific Generalized Anxiety Disorder Market

12. Europe, Middle East & Africa Generalized Anxiety Disorder Market

13. Competitive Landscape

Companies Mentioned

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â